Mr. Solander's practice has embraced a wide range of technologies including, most recently, prescription anti-psoriasis medications, protein synthesis, anti-platelet inhibitor drugs, anti-cancer drugs, polymorphs, anti-ulcer drugs, structural composites, new battery technologies, and prescription sleep aids. Mr. Solander also counsels clients concerning noninfringement, invalidity and freedom to practice in these and other fields.
Some of the companies that he has represented or advised include Bristol-Myers Squibb, Cytec, Debiopharm, Merck, Monsanto, Novartis, Sanofi-Aventis, Sepracor and Yamanouchi Pharmaceutical.
Mr. Solander was recognized for his outstanding work in the patent category in Chambers USA 2008, 2009, 2010 and 2011 and described as "a litigator with great courtroom instincts." He was listed in Legal Media Group Guide to the World’s Leading Patent Law Practitioners 2007 and was listed in IAM Life Sciences 250- The World's Leading Life Sciences Patent Litigators 2010. He was also listed in IAM 250: The World’s Leading Patent Litigators 2011. Mr. Solander was recognized in the 2011 edition of Who’s Who of Patent Lawyers. He was listed in the PLC Which Lawyer 2012 edition for IP: patent litigation. Recognized in Chambers USA 2012 as a leading individual that is “terrific – he really gets into the case, knows the science, is up to date on the law and works well with witnesses.” He was also recognized in IAM Patent 1000 2012 as a leading attorney.